Aspen Neuroscience has filed a notice of an exempt offering of securities to raise $40,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Aspen Neuroscience is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Howard Federoff played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Aspen Neuroscience
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinsons disease (PD) and extending across the brain and affected organs.
To learn more about Aspen Neuroscience, visit http://www.aspenneuroscience.com/
Contact:
Howard Federoff, Chief Executive Officer
858-263-1222
SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved